Vera Therapeutics, Inc. Lease, Cost
Vera Therapeutics, Inc. (VERA) reported Lease, Cost of $761.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- Vera Therapeutics, Inc. lease, cost for the quarter ending 2025-12-31 was $193.00K, a 36.30% decline year-over-year.
- Vera Therapeutics, Inc. lease, cost for the quarter ending 2025-09-30 was $176.00K, a 9.74% decline year-over-year.
- Vera Therapeutics, Inc. lease, cost for the quarter ending 2025-06-30 was $194.00K, a 11.49% increase year-over-year.
- Vera Therapeutics, Inc. lease, cost for the quarter ending 2025-03-31 was $198.00K, a 13.79% increase year-over-year.
- Vera Therapeutics, Inc. lease, cost for fiscal 2025 was $761.00K, a 7.08% decline from fiscal 2024.
- Vera Therapeutics, Inc. lease, cost for fiscal 2024 was $819.00K, a 23.53% increase from fiscal 2023.
- Vera Therapeutics, Inc. lease, cost for fiscal 2023 was $663.00K, a 47.33% increase from fiscal 2022.
- Vera Therapeutics, Inc. lease, cost for fiscal 2022 was $450.00K, a 1775.00% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $369.00K derived: sum of 2 quarters · filed 2026-02-26 | $563.00K derived: sum of 3 quarters · filed 2026-02-26 | $761.00K 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $176.00K 10-Q · filed 2025-11-05 | $370.00K derived: sum of 2 quarters · filed 2025-11-05 | $568.00K 10-Q · filed 2025-11-05 | $871.00K derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2025-06-30 | $194.00K 10-Q · filed 2025-08-05 | $392.00K 10-Q · filed 2025-08-05 | $695.00K derived: sum of 3 quarters · filed 2026-02-26 | $890.00K derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2025-03-31 | $198.00K 10-Q · filed 2025-05-07 | $501.00K derived: sum of 2 quarters · filed 2026-02-26 | $696.00K derived: sum of 3 quarters · filed 2026-02-26 | $870.00K derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-12-31 | $303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $498.00K derived: sum of 2 quarters · filed 2026-02-26 | $672.00K derived: sum of 3 quarters · filed 2026-02-26 | $819.00K 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $195.00K 10-Q · filed 2025-11-05 | $182.00K 10-Q · filed 2024-11-07 | $369.00K derived: sum of 2 quarters · filed 2025-11-05 | $516.00K 10-Q · filed 2025-11-05 | $478.00K 10-Q · filed 2024-11-07 | $719.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $174.00K 10-Q · filed 2025-08-05 | $162.00K 10-Q · filed 2024-08-08 | $350.00K 10-Q · filed 2025-08-05 | $325.00K 10-Q · filed 2024-08-08 | $524.00K derived: sum of 3 quarters · filed 2026-02-26 | $686.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $174.00K 10-Q · filed 2025-05-07 | $162.00K 10-Q · filed 2024-05-10 | $350.00K derived: sum of 2 quarters · filed 2026-02-26 | $512.00K derived: sum of 3 quarters · filed 2026-02-26 | $674.00K derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $338.00K derived: sum of 2 quarters · filed 2026-02-26 | $500.00K derived: sum of 3 quarters · filed 2026-02-26 | $663.00K 10-K · filed 2026-02-26 | $649.00K 10-K · filed 2024-03-27 | |||
| 2023-09-30 | $162.00K 10-Q · filed 2024-11-07 | $324.00K derived: sum of 2 quarters · filed 2024-11-07 | $487.00K 10-Q · filed 2024-11-07 | $648.00K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $162.00K 10-Q · filed 2024-08-08 | $325.00K 10-Q · filed 2024-08-08 | $486.00K derived: sum of 3 quarters · filed 2024-08-08 | $598.00K derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $162.00K 10-Q · filed 2024-05-10 | $324.00K derived: sum of 2 quarters · filed 2024-05-10 | $436.00K derived: sum of 3 quarters · filed 2024-05-10 | $524.00K derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $274.00K derived: sum of 2 quarters · filed 2024-03-27 | $362.00K derived: sum of 3 quarters · filed 2024-03-27 | $450.00K 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $112.00K 10-Q · filed 2023-11-09 | $200.00K derived: sum of 2 quarters · filed 2023-11-09 | $288.00K 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | $88.00K 10-Q · filed 2023-08-10 | $175.00K 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | $88.00K 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $24.00K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |